Larson Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$541K Buy
3,817
+2,281
+149% +$367K 0.01% 564
2026
Q2
$259K Sell
1,536
-6
-0.4% -$890 0.01% 745
2026
Q1
$203K Buy
1,542
+537
+53% +$71.3K 0.01% 715
2025
Q4
$143K Buy
1,005
+248
+33% +$35.9K ﹤0.01% 804
2025
Q3
$106K Buy
757
+47
+7% +$6.37K ﹤0.01% 876
2025
Q2
$89.2K Buy
710
+310
+78% +$35.6K ﹤0.01% 888
2025
Q1
$44.2K Sell
400
-1,013
-72% -$128K ﹤0.01% 1075
2024
Q4
$193K Buy
1,413
+12
+0.9% +$1.48K 0.01% 573
2024
Q3
$161K Sell
1,401
-492
-26% -$67.4K 0.01% 628
2024
Q2
$261K Sell
1,893
-320
-14% -$43.9K 0.02% 399
2024
Q1
$305K Sell
2,213
-44
-2% -$6.01K 0.02% 313
2023
Q4
$297K Buy
2,257
+2,246
+20,418% +$259K 0.03% 273
2023
Q3
$1.24K Buy
+11
New +$1.16K ﹤0.01% 1455
2023
Q1
– Sell
-2,331
Closed -$278K – 1586
2022
Q4
$278K Buy
2,331
+391
+20% +$45.8K 0.03% 257
2022
Q3
$206K Buy
1,940
+122
+7% +$12.4K 0.03% 267
2022
Q2
$177K Buy
+1,818
New +$168K 0.03% 204

Other funds holding NBIX

Larson Financial Group's NBIX Position: Q3 2026 in Review

Larson Financial Group increased its Neurocrine Biosciences (NBIX) stake by 149% in Q3 2026, buying an estimated $367K and bringing the position to 3,817 shares worth $541K. The position accounts for 0.01% of the portfolio, ranked #564.

Larson Financial Group first reported a position in NBIX in Q2 2022 and has held it in 16 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Larson Financial Group held 3,817 shares of Neurocrine Biosciences worth $541K as of Q3 2026.
  • Larson Financial Group bought 2,281 Neurocrine Biosciences shares in Q3 2026, an estimated $367K.
  • Neurocrine Biosciences made up 0.01% of Larson Financial Group's portfolio in Q3 2026, its #564 holding.
  • Larson Financial Group first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 16 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.